Masimo (NASDAQ: MASI) announced today that Deutsches Herzzentrum Berlin (DHZB / German Heart Center Berlin) in Berlin, Germany, has adopted Masimo’s SedLine® Brain Function Monitoring and O3™ Regional Oximetry technologies to monitor patients in the operating room and intensive care unit.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160707005661/en/
“Our non-profit hospital performs over 32,000 treatments each year. Easy access to advanced parameters and the data they provide are very important for our patients, many of whom are undergoing especially complex and critical operations,” stated Prof. Dr. Hermann Kuppe, Director of the Department of Anesthesiology at DHZB, “Masimo’s technology allows us to access multiple parameters quickly and noninvasively from one monitor.”
SedLine brain function monitoring provides four channels of electroencephalogram (EEG) to help clinicians better understand the effects of anesthesia on the brain. SedLine monitors the effects of anesthesia and sedation by monitoring electrical activity on both sides of the brain. O3 regional oximetry provides regional oxygen saturation (rSO2) and reference arterial oxygen saturation (SpO2) information, helping clinicians detect regional hypoxemia that pulse oximetry alone can miss.
“The innovative treatment programs at Deutsches Herzzentrum Berlin have helped it to become recognized as one of the world’s leading centers for cardiovascular medicine and transplantation. They have doctors, medical students and scientific researchers from around the world apply to visit the hospital as clinical observers every year,” stated Joe Kiani, Founder and CEO of Masimo. “We are happy to see them adopt our SedLine and O3 technologies and are impressed by their focus on patient safety.”
DHZB is a specialist hospital dedicated to the diagnosis and treatment of cardiovascular and thoracic diseases, the implantation of mechanical circulatory support systems, and heart and lung transplantations. A cooperative partnership with Charité-Universitätsmedizin Berlin, each year the hospital performs more than 6,700 operations, including 2,400 operations using heart-lung machines. DHZB treats more than 7,200 inpatients and 24,000 outpatients annually. The hospital has 194 beds, 71 of which are in intensive care. Since 2002, DHZB has received certification by KTQ, the national quality control board, recognizing the high standard of care DHZB provides. DHZB and its subsidiaries employ 1,300 people, including 190 doctors and almost 500 nurses.
@MasimoInnovates | #Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect™ (MOC-9™) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7™ wearable patient monitor and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at www.masimo.com. All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo’s SedLine® and O3™ technologies. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo’s unique noninvasive measurement technologies, including Masimo’s SedLine® and O3™ technologies, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the “Risk Factors” section of our most recent reports filed with the Securities and Exchange Commission (“SEC”), which may be obtained for free at the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today’s date. We do not undertake any obligation to update, amend or clarify these statements or the “Risk Factors” contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160707005661/en/
MULTIMEDIA AVAILABLE :